Maria Gore
Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Angiopathies | 6 | 2015 | 265 | 1.370 |
Why?
| | Cardiovascular Diseases | 10 | 2020 | 2219 | 1.190 |
Why?
| | Troponin T | 3 | 2020 | 63 | 1.020 |
Why?
| | Diabetes Mellitus, Type 2 | 14 | 2016 | 2623 | 1.010 |
Why?
| | Myocardial Infarction | 7 | 2015 | 1215 | 0.960 |
Why?
| | Blood Donors | 2 | 2015 | 145 | 0.740 |
Why?
| | Hypoglycemic Agents | 7 | 2015 | 1412 | 0.680 |
Why?
| | Diabetes Mellitus | 3 | 2015 | 1101 | 0.650 |
Why?
| | Veterinary Medicine | 1 | 2019 | 12 | 0.580 |
Why?
| | Prediabetic State | 3 | 2015 | 250 | 0.510 |
Why?
| | Hospice Care | 1 | 2019 | 230 | 0.450 |
Why?
| | Pain | 2 | 2019 | 790 | 0.430 |
Why?
| | Thiazolidinediones | 5 | 2015 | 142 | 0.420 |
Why?
| | Hyperglycemia | 2 | 2015 | 384 | 0.390 |
Why?
| | Risk Reduction Behavior | 1 | 2015 | 220 | 0.390 |
Why?
| | Coronary Disease | 2 | 2015 | 380 | 0.390 |
Why?
| | Heart Failure | 6 | 2015 | 2329 | 0.370 |
Why?
| | Biomarkers | 10 | 2020 | 4340 | 0.360 |
Why?
| | Arginine | 1 | 2013 | 264 | 0.350 |
Why?
| | Precision Medicine | 1 | 2016 | 462 | 0.350 |
Why?
| | Public Health | 1 | 2015 | 574 | 0.310 |
Why?
| | Risk Assessment | 9 | 2020 | 3712 | 0.300 |
Why?
| | Stroke Volume | 3 | 2011 | 652 | 0.290 |
Why?
| | Neoplasms, Connective Tissue | 1 | 2008 | 3 | 0.280 |
Why?
| | Osteomalacia | 1 | 2008 | 4 | 0.280 |
Why?
| | Hypophosphatemia | 1 | 2008 | 16 | 0.280 |
Why?
| | Nose Neoplasms | 1 | 2008 | 22 | 0.280 |
Why?
| | Patient Safety | 1 | 2012 | 352 | 0.270 |
Why?
| | Risk Factors | 13 | 2020 | 10921 | 0.270 |
Why?
| | Cardiovascular System | 1 | 2009 | 137 | 0.250 |
Why?
| | Metformin | 1 | 2011 | 328 | 0.250 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2016 | 3930 | 0.230 |
Why?
| | Troponin | 2 | 2016 | 50 | 0.230 |
Why?
| | Natriuretic Peptide, Brain | 3 | 2020 | 110 | 0.220 |
Why?
| | Insulin Resistance | 1 | 2013 | 1247 | 0.220 |
Why?
| | Sex Distribution | 2 | 2015 | 382 | 0.210 |
Why?
| | Texas | 6 | 2014 | 280 | 0.200 |
Why?
| | Humans | 32 | 2020 | 146342 | 0.190 |
Why?
| | Hospitalization | 2 | 2012 | 2475 | 0.190 |
Why?
| | Oxygen Consumption | 4 | 2014 | 721 | 0.190 |
Why?
| | Middle Aged | 20 | 2020 | 36619 | 0.180 |
Why?
| | Obesity | 2 | 2015 | 3131 | 0.180 |
Why?
| | Rest | 2 | 2013 | 126 | 0.180 |
Why?
| | Aged | 15 | 2020 | 26432 | 0.170 |
Why?
| | Male | 23 | 2020 | 73396 | 0.160 |
Why?
| | Female | 23 | 2020 | 79499 | 0.160 |
Why?
| | Peptide Fragments | 2 | 2020 | 693 | 0.160 |
Why?
| | Sex Factors | 4 | 2017 | 2107 | 0.160 |
Why?
| | Predictive Value of Tests | 3 | 2015 | 2113 | 0.160 |
Why?
| | Cohort Studies | 4 | 2015 | 6077 | 0.160 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2020 | 75 | 0.160 |
Why?
| | C-Reactive Protein | 2 | 2020 | 429 | 0.150 |
Why?
| | Insulin | 1 | 2011 | 2525 | 0.150 |
Why?
| | Education, Veterinary | 1 | 2019 | 7 | 0.150 |
Why?
| | Pets | 1 | 2019 | 28 | 0.140 |
Why?
| | Cross-Sectional Studies | 6 | 2017 | 5899 | 0.140 |
Why?
| | Evidence-Based Medicine | 2 | 2012 | 731 | 0.140 |
Why?
| | Myocardium | 3 | 2014 | 948 | 0.130 |
Why?
| | Chi-Square Distribution | 3 | 2012 | 517 | 0.120 |
Why?
| | Electrocardiography | 1 | 2020 | 667 | 0.120 |
Why?
| | Glycemic Index | 1 | 2016 | 26 | 0.120 |
Why?
| | Universities | 1 | 2019 | 451 | 0.120 |
Why?
| | Cardiac Output | 2 | 2013 | 176 | 0.120 |
Why?
| | Transcutaneous Electric Nerve Stimulation | 2 | 2007 | 23 | 0.120 |
Why?
| | Early Diagnosis | 2 | 2014 | 251 | 0.120 |
Why?
| | Prospective Studies | 6 | 2015 | 8123 | 0.120 |
Why?
| | Troponin I | 1 | 2016 | 74 | 0.110 |
Why?
| | Atherosclerosis | 3 | 2014 | 410 | 0.110 |
Why?
| | Aged, 80 and over | 3 | 2020 | 8391 | 0.110 |
Why?
| | Homoarginine | 1 | 2014 | 2 | 0.110 |
Why?
| | Prognosis | 3 | 2013 | 4351 | 0.110 |
Why?
| | Age Distribution | 1 | 2015 | 399 | 0.100 |
Why?
| | Hypercholesterolemia | 1 | 2015 | 95 | 0.100 |
Why?
| | Time Factors | 4 | 2012 | 7109 | 0.100 |
Why?
| | Diabetic Cardiomyopathies | 1 | 2014 | 34 | 0.100 |
Why?
| | Reference Values | 2 | 2014 | 796 | 0.100 |
Why?
| | Follow-Up Studies | 3 | 2014 | 5439 | 0.100 |
Why?
| | Blood Chemical Analysis | 1 | 2014 | 109 | 0.100 |
Why?
| | Biological Assay | 1 | 2014 | 133 | 0.100 |
Why?
| | Proportional Hazards Models | 2 | 2014 | 1331 | 0.100 |
Why?
| | Cholesterol | 1 | 2015 | 411 | 0.100 |
Why?
| | Triglycerides | 2 | 2014 | 527 | 0.090 |
Why?
| | Physical Fitness | 1 | 2014 | 209 | 0.090 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2014 | 253 | 0.090 |
Why?
| | Life Style | 1 | 2015 | 496 | 0.090 |
Why?
| | United States | 3 | 2015 | 16136 | 0.090 |
Why?
| | Urban Population | 1 | 2015 | 497 | 0.090 |
Why?
| | Curriculum | 1 | 2019 | 1079 | 0.090 |
Why?
| | Renal Insufficiency | 1 | 2014 | 173 | 0.090 |
Why?
| | Drug Approval | 1 | 2012 | 94 | 0.090 |
Why?
| | Blood Glucose | 2 | 2014 | 2360 | 0.080 |
Why?
| | Survival Analysis | 2 | 2012 | 1378 | 0.080 |
Why?
| | Ventricular Function | 1 | 2011 | 53 | 0.080 |
Why?
| | Pilot Projects | 2 | 2014 | 1888 | 0.080 |
Why?
| | Socioeconomic Factors | 1 | 2015 | 1327 | 0.080 |
Why?
| | Edema | 1 | 2011 | 131 | 0.080 |
Why?
| | Diabetic Nephropathies | 1 | 2014 | 320 | 0.080 |
Why?
| | Rural Population | 1 | 2015 | 677 | 0.080 |
Why?
| | Cardiac Catheterization | 1 | 2013 | 571 | 0.070 |
Why?
| | Adult | 9 | 2017 | 41087 | 0.070 |
Why?
| | Diabetes Complications | 1 | 2011 | 219 | 0.070 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 228 | 0.070 |
Why?
| | Sensitivity and Specificity | 1 | 2014 | 1998 | 0.070 |
Why?
| | Multivariate Analysis | 1 | 2012 | 1543 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2014 | 2921 | 0.070 |
Why?
| | Colorado | 1 | 2019 | 4595 | 0.070 |
Why?
| | Ilium | 1 | 2008 | 31 | 0.070 |
Why?
| | Coronary Artery Disease | 2 | 2015 | 751 | 0.070 |
Why?
| | Blood Pressure | 1 | 2015 | 1765 | 0.070 |
Why?
| | Quinolines | 1 | 2009 | 191 | 0.070 |
Why?
| | Delayed Diagnosis | 1 | 2008 | 102 | 0.070 |
Why?
| | Hospital Mortality | 1 | 2012 | 1051 | 0.070 |
Why?
| | Survival Rate | 1 | 2012 | 2092 | 0.070 |
Why?
| | United Kingdom | 1 | 2009 | 377 | 0.060 |
Why?
| | Anticholesteremic Agents | 1 | 2009 | 156 | 0.060 |
Why?
| | Young Adult | 2 | 2015 | 14330 | 0.060 |
Why?
| | Logistic Models | 1 | 2012 | 2126 | 0.060 |
Why?
| | Registries | 2 | 2014 | 2400 | 0.060 |
Why?
| | Comorbidity | 1 | 2012 | 1665 | 0.060 |
Why?
| | Clinical Trials as Topic | 1 | 2012 | 1064 | 0.060 |
Why?
| | Mass Screening | 1 | 2015 | 1307 | 0.060 |
Why?
| | Ambulances | 1 | 2007 | 52 | 0.060 |
Why?
| | Emergency Medical Technicians | 1 | 2007 | 40 | 0.060 |
Why?
| | Hypertension | 1 | 2015 | 1272 | 0.060 |
Why?
| | Age Factors | 1 | 2014 | 3347 | 0.060 |
Why?
| | Hip Fractures | 1 | 2007 | 88 | 0.060 |
Why?
| | Atrial Natriuretic Factor | 1 | 2005 | 54 | 0.060 |
Why?
| | Biopsy | 1 | 2008 | 1075 | 0.050 |
Why?
| | Adolescent | 2 | 2015 | 22557 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 1 | 2014 | 1408 | 0.050 |
Why?
| | Transportation of Patients | 1 | 2005 | 62 | 0.050 |
Why?
| | Models, Biological | 1 | 2011 | 1761 | 0.050 |
Why?
| | Low Back Pain | 1 | 2005 | 109 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2009 | 1763 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2012 | 11821 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2009 | 3416 | 0.040 |
Why?
| | Exercise Test | 2 | 2014 | 637 | 0.040 |
Why?
| | Ventricular Function, Left | 2 | 2014 | 541 | 0.040 |
Why?
| | Double-Blind Method | 3 | 2011 | 2070 | 0.040 |
Why?
| | Hemodynamics | 2 | 2013 | 1114 | 0.030 |
Why?
| | Animals | 1 | 2019 | 38107 | 0.030 |
Why?
| | Prevalence | 2 | 2014 | 2861 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 3 | 2014 | 3926 | 0.030 |
Why?
| | Proton Magnetic Resonance Spectroscopy | 1 | 2014 | 20 | 0.030 |
Why?
| | Contraindications | 1 | 2014 | 88 | 0.030 |
Why?
| | Propanolamines | 1 | 2014 | 40 | 0.030 |
Why?
| | Carbazoles | 1 | 2014 | 53 | 0.030 |
Why?
| | Urban Health | 1 | 2014 | 95 | 0.020 |
Why?
| | Lymphotoxin beta Receptor | 1 | 2013 | 2 | 0.020 |
Why?
| | Models, Cardiovascular | 1 | 2013 | 194 | 0.020 |
Why?
| | Glycation End Products, Advanced | 1 | 2013 | 84 | 0.020 |
Why?
| | Monitoring, Physiologic | 1 | 2013 | 279 | 0.020 |
Why?
| | ROC Curve | 1 | 2013 | 617 | 0.020 |
Why?
| | Placebos | 1 | 2011 | 192 | 0.020 |
Why?
| | Aorta | 1 | 2014 | 440 | 0.020 |
Why?
| | Plasma Volume | 1 | 2011 | 19 | 0.020 |
Why?
| | Hematocrit | 1 | 2011 | 108 | 0.020 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2014 | 391 | 0.020 |
Why?
| | Molecular Weight | 1 | 2011 | 295 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2014 | 561 | 0.020 |
Why?
| | Serum Albumin | 1 | 2011 | 147 | 0.020 |
Why?
| | Ultrasonography | 1 | 2014 | 788 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2011 | 313 | 0.020 |
Why?
| | Adiposity | 1 | 2014 | 533 | 0.020 |
Why?
| | Adiponectin | 1 | 2011 | 243 | 0.020 |
Why?
| | Linear Models | 1 | 2011 | 857 | 0.020 |
Why?
| | Regression Analysis | 1 | 2011 | 999 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2011 | 453 | 0.020 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2011 | 627 | 0.020 |
Why?
| | Incidence | 1 | 2014 | 2936 | 0.020 |
Why?
| | Weight Gain | 1 | 2011 | 562 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2014 | 3017 | 0.010 |
Why?
| | Decision Making | 1 | 2013 | 993 | 0.010 |
Why?
| | Cytokines | 1 | 2013 | 2081 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2007 | 1298 | 0.010 |
Why?
| | Body Mass Index | 1 | 2011 | 2458 | 0.010 |
Why?
| | Pain Measurement | 1 | 2005 | 573 | 0.010 |
Why?
| | Acute Disease | 1 | 2005 | 1038 | 0.010 |
Why?
| | Heart Rate | 1 | 2005 | 846 | 0.010 |
Why?
| | Emergency Medical Services | 1 | 2007 | 680 | 0.010 |
Why?
| | Anxiety | 1 | 2005 | 1125 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2013 | 17438 | 0.010 |
Why?
|
|
Gore's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|